EP1323824A3 - Utilisation du facteur-2 de croissance des kératinocytes humain pour la préparation d'une composition pharmaceutique - Google Patents

Utilisation du facteur-2 de croissance des kératinocytes humain pour la préparation d'une composition pharmaceutique Download PDF

Info

Publication number
EP1323824A3
EP1323824A3 EP03006708A EP03006708A EP1323824A3 EP 1323824 A3 EP1323824 A3 EP 1323824A3 EP 03006708 A EP03006708 A EP 03006708A EP 03006708 A EP03006708 A EP 03006708A EP 1323824 A3 EP1323824 A3 EP 1323824A3
Authority
EP
European Patent Office
Prior art keywords
disclosed
polypeptide
preparation
pharmaceutical compositions
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03006708A
Other languages
German (de)
English (en)
Other versions
EP1323824A2 (fr
Inventor
Joachim R. Gruber
Patrick J. Dillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1323824A2 publication Critical patent/EP1323824A2/fr
Publication of EP1323824A3 publication Critical patent/EP1323824A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
EP03006708A 1995-02-14 1995-02-14 Utilisation du facteur-2 de croissance des kératinocytes humain pour la préparation d'une composition pharmaceutique Withdrawn EP1323824A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/001790 WO1996025422A1 (fr) 1995-02-14 1995-02-14 Facteur-2 de croissance des keratinocytes
EP95911700A EP0815115B1 (fr) 1995-02-14 1995-02-14 Facteur-2 de croissance des keratinocytes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP95911700A Division EP0815115B1 (fr) 1995-02-14 1995-02-14 Facteur-2 de croissance des keratinocytes

Publications (2)

Publication Number Publication Date
EP1323824A2 EP1323824A2 (fr) 2003-07-02
EP1323824A3 true EP1323824A3 (fr) 2004-01-21

Family

ID=22248657

Family Applications (2)

Application Number Title Priority Date Filing Date
EP95911700A Expired - Lifetime EP0815115B1 (fr) 1995-02-14 1995-02-14 Facteur-2 de croissance des keratinocytes
EP03006708A Withdrawn EP1323824A3 (fr) 1995-02-14 1995-02-14 Utilisation du facteur-2 de croissance des kératinocytes humain pour la préparation d'une composition pharmaceutique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP95911700A Expired - Lifetime EP0815115B1 (fr) 1995-02-14 1995-02-14 Facteur-2 de croissance des keratinocytes

Country Status (10)

Country Link
EP (2) EP0815115B1 (fr)
JP (1) JP3774230B2 (fr)
KR (1) KR19980702186A (fr)
AT (1) ATE241639T1 (fr)
AU (1) AU708868B2 (fr)
CA (1) CA2210444C (fr)
DE (1) DE69530944T2 (fr)
DK (1) DK0815115T3 (fr)
NZ (1) NZ282146A (fr)
WO (1) WO1996025422A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
WO1997020929A1 (fr) * 1995-12-07 1997-06-12 Sumitomo Pharmaceuticals Company, Limited Facteur de croissance des fibroblastes fgf-10
ES2212121T3 (es) * 1996-08-13 2004-07-16 Human Genome Sciences, Inc. Mutantes de factor-2 de crecimiento queranocitico (kgf-2 o factor -12 de crecimiento fibroblastico, fgf-12).
DK0935652T3 (da) * 1996-10-15 2004-07-26 Amgen Inc Keratinocyt vækstfaktor-2 produkter
AU775027C (en) * 1996-10-15 2005-12-08 Biovitrum Ab (Publ) Keratinocyte growth factor-2 products
EP1452205B1 (fr) * 1996-10-15 2007-11-28 Amgen Inc. Utilisation du facteur de croissance des kératinocytes -2
EP1473366A1 (fr) * 1996-10-15 2004-11-03 Amgen Inc. Produits a base du facteur de croissance 2 des keratinocytes
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
ATE259651T1 (de) * 1996-10-15 2004-03-15 Amgen Inc Verwendung von keratinocyten-wachstumsfaktor-2
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
JP2001526239A (ja) 1997-12-22 2001-12-18 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 角質細胞増殖因子−２製剤
CA2320515A1 (fr) * 1998-02-13 1999-08-19 Human Genome Sciences, Inc. Utilisations therapeutiques du facteur-2 de croissance de keratinocyte
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
CA2383001A1 (fr) 1999-12-10 2001-06-14 Anticancer, Inc. Procede permettant l'implantation de genes dans un mammifere
ATE297751T1 (de) 2000-03-20 2005-07-15 Pfizer Prod Inc Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0619370A1 (fr) * 1993-03-26 1994-10-12 Amgen Inc. Facteur de croissance des kératinocytes pour son utilisation dans une méthode de traitement thérapeutique du corps humain ou animal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0619370A1 (fr) * 1993-03-26 1994-10-12 Amgen Inc. Facteur de croissance des kératinocytes pour son utilisation dans une méthode de traitement thérapeutique du corps humain ou animal

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FINCH, P.W. ET AL.: "Human KGF Is FGF-Related with Properties of a Paracrine Effector of Epithelial Cell Growth", SCIENCE, vol. 245, no. 4919, 18 August 1989 (1989-08-18), pages 752 - 755, XP000081363 *
MASON, I.J. ET AL.: "FGF-7 (keratinocyte growth factor) expression during mouse development suggests roles in myogenesis, forebrain regionalisation and epithelial-mesenchymal interactions", MECHANISMS OF DEVELOPMENT, vol. 45, no. 1, January 1994 (1994-01-01), pages 15 - 30, XP000852854 *

Also Published As

Publication number Publication date
JP3774230B2 (ja) 2006-05-10
NZ282146A (en) 1999-10-28
DK0815115T3 (da) 2003-09-15
WO1996025422A1 (fr) 1996-08-22
EP0815115A4 (fr) 1999-09-22
DE69530944D1 (de) 2003-07-03
AU1917195A (en) 1996-09-04
CA2210444A1 (fr) 1996-08-22
CA2210444C (fr) 2003-07-29
EP0815115B1 (fr) 2003-05-28
JPH10509328A (ja) 1998-09-14
EP1323824A2 (fr) 2003-07-02
AU708868B2 (en) 1999-08-12
KR19980702186A (ko) 1998-07-15
EP0815115A1 (fr) 1998-01-07
ATE241639T1 (de) 2003-06-15
DE69530944T2 (de) 2004-03-11

Similar Documents

Publication Publication Date Title
EP1323824A3 (fr) Utilisation du facteur-2 de croissance des kératinocytes humain pour la préparation d'une composition pharmaceutique
ES2068791T1 (es) Metodos y acido desoxirribonucleico para la preparacion de proteina de factor de tejido.
AU6046796A (en) Human vascular endothelial growth factor 2
IL112878A0 (en) Fibroblast growth factor-10 polypeptide and its production dna(rna) encoding it and pharmaceutical compositions containing it
RU94045281A (ru) Иммуноконъюгаты, способ получения иммуноконъюгата, фармацевтическая композиция, применение иммуноконъюгата
DE69428214D1 (de) Transformierender wachstumsfaktor alpha h1
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
ATE337339T1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
MX9706204A (es) Factor 2 de crecimiento de queratinocitos.
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
MX9707617A (es) Factor de crecimiento de criptina humano.
DE69636232T2 (de) Wachstumsfaktor HTTER36
CN116804050A (zh) 经修饰的角蛋白、生物材料及其应用
ES2194049T3 (es) Factor-2 de crecimiento de queratinocitos.
Prakash et al. Fibrosin: a novel lymphokine in wound healing
MX9708493A (es) Factor 15 de crecimiento de fibroblastos.
MX9709570A (es) Factor de crecimiento 3 endotelial, vascular, humano.
MX9707897A (es) Factor-11 del crecimiento de fibroblastos.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 0815115

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRUBER, JOACHIM R.

Inventor name: DILLON, PATRICK J.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DILLON, PATRICK J.

Inventor name: GRUBER, JOACHIM R.

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040722